Some of the key findings from this report prepared by BIO are:
• Venture Capital Investment: A record $12.3 billion in venture funding went to U.S. emerging therapeutic companies in 2018, with 95% toward novel R&D and only 5% into drug improvement R&D for existing drugs. Venture investment into innovative U.S. therapeutic companies continues to outpace Europe (5.7x), Asia (4.6x), and the rest of the world (35x) despite a record $5.2 billion for Ex-U.S. companies. First-time Series A financing broke a record in the U.S. with 109 new companies receiving funding, indicating a robust interest in early-stage biotech.
• IPOs: U.S.-based R&D-stage emerging therapeutic companies were able to raise $5.1 billion from 47 IPOs in 2018, a record dollar amount and the 2nd highest number of IPOs in a decade. Ex-U.S. based R&D-stage emerging therapeutic companies raised $2.3 billion from 22 IPOs, a record dollar amount.
• Follow-On Public Offerings: Public market follow-on offerings for U.S.-based R&D-stage emerging therapeutic companies remained strong, with $11.5 billion raised in 2018 across 118 offerings (valued at $10 million or more). Ex-U.S.-based R&D-stage emerging therapeutic companies raised $3.2 billion from 28 transactions in 2018, a record year in dollars raised and the number of financings.
• Licensing: Global R&D-stage licensing deals (valued at $10 million or more) brought in $9.1 billion in upfront payments, a 107% increase over 2017. Asian emerging company assets accounted for a record 18 of these deals in 2018, albeit reaching only 11% of the total funds raised.
• Acquisitions: The number of global R&D-stage emerging therapeutic company acquisitions rebounded from a decade low of 21 in 2017 to 28 in 2018. A record $32.5 billion was paid upfront for the 28 R&D-stage companies. U.S.-based companies accounted for 66% of the R&D-stage emerging company acquisition targets. The number of global market-stage emerging therapeutic company acquisitions reached a decade low of four acquisitions for $2.2 billion (upfront).
• Global Clinical Pipeline: Total active clinical-stage programs reached a record 6,984 with emerging companies accounting for 73% of these programs. Emerging companies have 94 marketing applications for new drugs (NDA/ BLAs) under review at the U.S. FDA. U.S.-based emerging companies account for 62% of these submissions.
• Venture Capital Investment: A record $12.3 billion in venture funding went to U.S. emerging therapeutic companies in 2018, with 95% toward novel R&D and only 5% into drug improvement R&D for existing drugs. Venture investment into innovative U.S. therapeutic companies continues to outpace Europe (5.7x), Asia (4.6x), and the rest of the world (35x) despite a record $5.2 billion for Ex-U.S. companies. First-time Series A financing broke a record in the U.S. with 109 new companies receiving funding, indicating a robust interest in early-stage biotech.
• IPOs: U.S.-based R&D-stage emerging therapeutic companies were able to raise $5.1 billion from 47 IPOs in 2018, a record dollar amount and the 2nd highest number of IPOs in a decade. Ex-U.S. based R&D-stage emerging therapeutic companies raised $2.3 billion from 22 IPOs, a record dollar amount.
• Follow-On Public Offerings: Public market follow-on offerings for U.S.-based R&D-stage emerging therapeutic companies remained strong, with $11.5 billion raised in 2018 across 118 offerings (valued at $10 million or more). Ex-U.S.-based R&D-stage emerging therapeutic companies raised $3.2 billion from 28 transactions in 2018, a record year in dollars raised and the number of financings.
• Licensing: Global R&D-stage licensing deals (valued at $10 million or more) brought in $9.1 billion in upfront payments, a 107% increase over 2017. Asian emerging company assets accounted for a record 18 of these deals in 2018, albeit reaching only 11% of the total funds raised.
• Acquisitions: The number of global R&D-stage emerging therapeutic company acquisitions rebounded from a decade low of 21 in 2017 to 28 in 2018. A record $32.5 billion was paid upfront for the 28 R&D-stage companies. U.S.-based companies accounted for 66% of the R&D-stage emerging company acquisition targets. The number of global market-stage emerging therapeutic company acquisitions reached a decade low of four acquisitions for $2.2 billion (upfront).
• Global Clinical Pipeline: Total active clinical-stage programs reached a record 6,984 with emerging companies accounting for 73% of these programs. Emerging companies have 94 marketing applications for new drugs (NDA/ BLAs) under review at the U.S. FDA. U.S.-based emerging companies account for 62% of these submissions.
No comments:
Post a Comment